info@auctorespublishing.com
+1-(302)-520-2644
+1-(302)-520-2644

Managing Frequently Relapsing Childhood Nephrotic Syndrome: A Novel Combination of Synacthen and Mycophenolate Mofetil

  1. Home
  2. Journals
  3. Clinical Medical Reviews and Reports
  4. Articles In Press
Submit Guidelines

Review | DOI: https://doi.org/10.31579/2690-8794/243

Managing Frequently Relapsing Childhood Nephrotic Syndrome: A Novel Combination of Synacthen and Mycophenolate Mofetil

  • Aamir Jalal Al-Mosawi *

Advisor doctor and expert trainer, The National Center of Training and Development and Baghdad Medical City, Baghdad, Iraq.

*Corresponding Author: Aamir Jalal Al-Mosawi, Advisor doctor and expert trainer, The National Center of Training and Development and Baghdad Medical City, Baghdad, Iraq.

Citation: Aamir Jalal Al-Mosawi, (2024), Managing Frequently Relapsing Childhood Nephrotic Syndrome: A Novel Combination of Synacthen and Mycophenolate Mofetil ,Clinical Medical Reviews and Reports; 6(10): DOI: 10.31579/2690-8794/243

Copyright: © 2024 Aamir Jalal Al-Mosawi,, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 08 November 2024 | Accepted: 15 November 2024 | Published: 22 November 2024

Keywords: Frequently relapsing nephrotic syndrome; challenging cases; innovative therapeutic strategies

Abstract

Childhood nephrotic syndrome is a prevalent renal disorder characterized by generalized edema due to hypoalbuminemia from heavy proteinuria. This syndrome can be classified as primary or secondary, with the majority of cases being primary. Historical perspectives on nephrotic syndrome illustrate significant advancements in understanding its pathology and treatment, beginning with early descriptions in the 15th century and evolving through the introduction of terms like "nephrosis."

Current management primarily relies on corticosteroids, but issues such as frequent relapses and steroid dependency necessitate alternative therapies. Recent approaches include the use of levamisole and mycophenolate mofetil, alongside the resurgence of intramuscular ACTH (synacthen) as a treatment option.

This article presents a case study of a boy with frequently relapsing steroid-dependent nephrotic syndrome, successfully treated with a novel combination of intramuscular synacthen and mycophenolate mofetil. 

This regimen effectively reduced the required dosage of steroids while minimizing associated adverse effects, particularly psychiatric symptoms. The findings underscore the potential for innovative therapeutic strategies in managing challenging cases of childhood nephrotic syndrome.

Introduction

Childhood nephrotic syndrome is primarily characterized by generalized edema due to hypoalbuminemia from significant proteinuria. Most cases are primary, with historical descriptions dating back to the 15th century. Key advancements in understanding and treating the syndrome include the introduction of terms like "nephrosis" by Friedrich von Müller and the distinction between inflammatory and non-inflammatory renal diseases by Franz Volhard and Theodor Fahr [1-18].

In 1484, Cornelus Roelans from Belgium likely described one of the first cases of nephrotic syndrome, noting whole-body swelling in a child [1]. In 1722, Theodore Zwinger from Basel provided a detailed account of childhood nephrotic syndrome, highlighting reduced urine output and attributing this to obstruction of the renal tubules [2].

In 1827, Richard Bright (Figure 1A) suggested that generalized edema combined with proteinuria is indicative of renal disease [3].

Figure-1A: Richard Bright (September 28, 1789-December 16, 1858) was an English physician

John Bostock (Figure 1B) observed a correlation between high urinary protein excretion and low serum protein levels [4].

Figure-1B: John Bostock, Jr. (June 29, 1773-August 6, 1846), an English physician and scientist

In 1846, George Johnson (Figure 1C) posited that the renal disease identified by Bright was a localized manifestation of a broader constitutional disorder. He also noted that not all cases of Richard Bright included albuminuria, which represents what Rayer called “Albuminous nephritis”, hinting at the heterogeneous nature of Bright's disease [5].

Figure-1C: George Johnson (November, 29 1818-June, 3 1896) was an English physician

 

In 1905, Friedrich von Müller (Figure 1D) introduced the term “nephrosis” to describe the histological changes in renal tubules which were thought to be degenerative, distinguishing these non-inflammatory disorders from “parenchymatous nephritis” which suggests an exudative and inflammatory disorder. Later, nephrosis has been used to describe the clinical condition which has been increasingly known nephrotic syndrome [6]. 

Figure-1D:Friedrich von Müller (September 17, 1858-November 18. 1941), a German physician

In 1914, Franz Volhard (Figure 1E) and Theodor Fahr (Figure 1F) reaffirmed the distinction between nephroses, a non-inflammatory disease and inflammatory nephritides in their classification of renal disorders [7].

Figure-1E: Franz Volhard (May 2, 1872-May 24, 1950), a German physician

 

Figure-1F: Karl Theodor Fahr (October 3, 1877-October 29, 1945), a German pathologist

Childhood nephrotic syndrome is primarily steroid-responsive, often characterized by frequent relapses and steroid dependence. Various steroids and synthetic adrenocorticotropic hormone (ACTH) analogs have been utilized since the 1950s [8-16].

Henry Lewis Barnett (Figure 1G) and his team were among the first to explore ACTH and cortisone treatment for nephrotic syndrome in 1950 [8]. 

Figure-1G: Henry Lewis Barnett (1914-2001), An American pioneer of pediatric nephrology

Gavin Arneil and Wilson reported the effective use of cortisone in 1952 and detailed treatment outcomes for 16 patients in 1953, emphasizing its role in inducing diuresis [10, 11].

By 1954, Lauson et al. noted the positive impact of ACTH on glomerular permeability in childhood nephrotic syndrome. 

Gavin Arneil (Figure 1H) was likely the first to report the use of prednisolone for treating nephrotic syndrome in 1956 [13].

Figure-1H: Gavin Cranston Arneil (March 7, 1923-January 21, 2018), a Scottish pioneer of pediatric nephrologist from Glasgow

In 1968, John Stewart Cameron (Figure 1I) demonstrated that the minimal change lesion, the predominant histopathological type in childhood nephrotic syndrome, is the only type that consistently responds to corticosteroid treatment within eight weeks [17].

Figure-1I: John Stewart Cameron (July 5, 1934-July 30, 2023), a British nephrologist

Chlorambucil and cyclophosphamide began to be used in the 1970s for challenging cases with significant steroid side effects [19-24].

The 1979 international study of kidney disease involved 54 children with frequently relapsing nephrotic syndrome, revealing that both treatment regimens were inadequate in preventing relapses [25].

Treatment strategies have evolved over the decades, with steroids being the primary therapy. However, issues such as frequent relapses and steroid dependency have led to the exploration of alternative treatments like levamisole and mycophenolate mofetil. Notably, intramuscular ACTH (synacthen) has gained attention for its beneficial effects on glomerular permeability and potential to alleviate psychiatric side effects associated with high-dose steroids.

In 1980, Tanphaichitr et al. highlighted the potential role of T-cell lymphocyte dysfunction in minimal change nephrotic syndrome, employing levamisole, an anthelmintic having immune stimulant property to treat seven children with minimal change nephrotic syndrome during relapses with positive outcomes.

Levamisole was used in a dose of 1.5 to 3.9 mg kg biweekly for one to six months. After Treatment was associated with a complete remission without the occurrence of side effects [26].

In 1984, Patrick Niaudet (Figure 1J) from Paris and his research team reported successful levamisole treatment in children with frequently relapsing nephrotic syndrome, leading to reduced corticosteroid doses without significant side effects [27].

 

Figure-1J: Patrick Niaudet, a pediatric nephrologist from France

They described the treatment of 30 cases of childhood frequently relapsing nephrotic syndrome with levamisole (2.5 mg/kg twice weekly) for a mean period of 9.9 months. Treatment in sixteen patients enabled marked reduction of corticosteroids without experiencing a relapse. However, levamisole was not effective in 14 patients. Seven patients who responded to levamisole therapy, experienced reduction of neutrophils to below 4×109/L. Three patients experienced transient granulocytopenia. 

Therefore, Niaudet and his research team suggested that levamisole can be useful option in frequently relapsing nephrotic syndrome, and with minimal side effects [27].

The British Association for Pediatric Nephrology supported levamisole, an immunostimulant agent as an alternative therapy in 1991, confirming its effectiveness in maintaining steroid-free remission.

They reported the treatment of 31 cases of frequently relapsing and dependent steroid nephrotic syndrome with levamisole (2.5 mg/kg on alternate days), while 30 patients received placebo for a maximum of 112 days. In both groups, prednisolone was progressively decreased and was discontinued by 56 days. 14 patients who received levamisole and only four patients who received placebo remained in remission at 112 days (log rank analysis p less than 0.01).The British Association for Pediatric Nephrology considered levamisole to be effective in maintaining a steroid-free remission, and it was not associated with important side effects [28].

Capodicasa et al. in 1986 and Brodehl in 1991 emphasized the possible occurrence of nephrotoxicity during the use of cyclosporine in the treatment of frequently relapsing nephrotic syndrome as evidenced by serum creatinine monitoring [29, 30].

Concerns regarding nephrotoxicity with cyclosporine prompted increased recommendations for levamisole in difficult cases of primary childhood nephrotic syndrome [31-39].

In 1998, Briggs from the United States suggested mycophenolate mofetil as a beneficial steroid-sparing agent for challenging cases of nephrotic syndrome. Mycophenolate mofetil can be used instead of cyclosporine in difficult cases of childhood nephrotic syndrome caused by minimal change disease and possibly by other glomerular disease [40].

Patients and methods

We utilized existing evidence to enhance the management of challenging childhood conditions such as frequently relapsing, steroid-dependent, and steroid-resistant nephrotic syndrome. We previously treated a boy (Figure 2A) with frequently relapsing steroid nephrotic syndrome who faced significant steroid toxicity, resulting in stunted growth due to prolonged high doses of prednisolone (2 mg/kg daily). His treatment involved an alternate-day regimen of levamisole combined with mycophenolate mofetil, significantly reducing the prednisolone dosage and its adverse effects.

This paper describes the use of a new therapeutic approach in the treatment of a second boy who had frequently relapsing nephrotic syndrome that didn’t respond to cyclosporine.

Figure 2A: A boy with frequently relapsing steroid nephrotic syndrome who faced significant steroid toxicity, resulting in stunted growth

Results

The boy first presented with nephrotic syndrome on August 20, 2020, at approximately seven years of age. By July 20, 2024, he was experiencing his seventh or eighth episode and was on oral prednisolone (10 mg daily) and cyclosporine (100 mg daily). His previous relapses had required high-dose prednisone, diuretics, and, at times, intravenous albumin.

Cyclosporine treatment was started before about 14 months. Previous relapses were treated with large dose oral prednisone and diuretics, and sometime he was receiving intravenous infusion of albumin. 

His father noted that the use of high-dose prednisone during relapses correlated with depressive symptoms that did not fully resolve with dose reductions.

On July 20, 2024, lab tests revealed normal renal function: serum creatinine at 0.4 mg/dL and blood urea at 25.5 mg/dL, with total serum protein at 4.2 g/dL and serum albumin at 1.5 g/dL. Urine analysis showed 200 mg/dL albumin (normal levels are <2>

The patient was not treated with the traditional large daily dose of prednisone, but he was treated with low-dose prednisolone, intramuscular synacthen (Tetracosactide, 1 mg weekly [Tetracosactride, a synthetic peptide with an amino acid sequence identical to the first 24 amino acids of corticotrophin]), and mycophenolate mofetil, starting at 1000 mg in two divided doses and increasing to 1500 mg daily after one week when urine showed 100 mg/dL albumin.

Prior to starting mycophenolate, complete blood studies indicated normal levels: Hemoglobin at 14.2 g/dL, WBC at 7.2 × 10^9/L, lymphocytes at 3.7 × 10^9/L (47.2%), and platelets at 352 × 10^9/L.

By August 3, 2024, blood tests showed Hemoglobin at 13.4 g/dL, WBC at 7.9 × 10^9/L, lymphocytes at 3.6 × 10^9/L (44.0%), and platelets at 332 × 10^9/L.

On August 17, 2024, the boy has received 5 intramuscular synacthen urine exam showed only trace amount of albumin. Intramuscular synacthen was stopped. Total serum protein was 7.0 g / dL and serum albumin was 4.2 g / d. Figure 2B illustrates the boy on October 12, 2024, with urine tests showing no detectable albumin.

Figure 2B: The boy on October 12, 2024, with urine tests showing no detectable albumin

Discussion

The beneficial effects of ACTH on glomerular permeability in childhood nephrotic syndrome were first reported in 1954 by Lauson et al. Subsequent studies (2004, 2010) indicated that ACTH could improve various nephritic syndromes by protecting podocytes from damage [42-47].

In 2004, Berg and Arnadottir reported that ACTH therapy was associated with improvement in a variety nephritic syn­drome [42]. 

In 2010, the work of Gong and Dworkin suggested that ACTH has a protective effect on podocytes as it can reduce foot-process effacement, podo­cyte apoptosis, and decrease the decline in glomerular expression of podocyte markers, including nephrin, vimentin, and podocin. Therefore it can have a beneficial effect when used in different types of glomerular disorders [44]. 

In 2011, Rujun Gong from the United States emphasized the renaissance of corticotropin treatment in nephrotic nephropathies [45].

Chlorambucil and cyclophosphamide and have used as early as the 1970s in difficult cases associated with significant steroid side effects [19-24].

In 1979, Wiggelinkhuizen and colleagues reported the treatment of thirteen childhood cases of frequently relapsing nephrotic syndrome with chlorambucil (Leukeran), a cytotoxic drug in a dose of 0.2 mg/kg/day for eight weeks. Treatment was associated with remission in 11 patients for an average of 31 months. No side-effects of therapy were observed in this study, but several grave complications of high-dosage therapy have been reported in the recent literature [23].

In 1980, Williams et al. reported the treatment of 59 childhood cases of frequently relapsing, steroid dependent and resistant idiopathic nephrotic syndrome with chlorambucil and prednisone for 5 to 15 weeks. 95% of the patients experienced remission at one year and 85% at 4 years. All patients except two experienced remissions lasting longer than steroid-induced remissions. Only eight other patients experienced one or more relapses after treatment [24]. 

The boy in this report was experiencing steroid-induced behavioral and psychiatric abnormalities mostly in the form of depressive mood.

In 2013, Youssef et al from Egypt reported a study which included thirty children with steroid sensitive nephrotic syndrome who were at remission or were receiving prednisolone in a low dose and experienced relapse. The study showed that prednisolone treatment in high doses was associated psychiatric abnormalities including anxiety and depression [41]. 

Several studies supported the potential of intramuscular synacthen to have a beneficial effect in childhood nephrotic syndrome [42-47]. 

Our current study highlights intramuscular synacthen's role in mitigating the psychiatric symptoms associated with high doses of prednisolone.

In 1896, Bartolomeo Gosio (Figure-3) reported the isolation of mycophenolic acid, an antibacterial from the mould Penicillium brevicompactum. The novel compound has an antibacterial property against anthrax bacterium. However, mycophenolic mofetil was not introduced into clinical use. 

In 1912, Alsberg and O.M. Black from the United States also reported its isolation. 

Mycophenolate mofetil, derived from mycophenolic acid, has been established as a safe and effective treatment for preventing immune rejection in organ transplants [48-50]. It has also shown promise in managing childhood nephrotic syndrome [52-67]

Mycophenolate mofetil (Cellcept), a derivative of mycophenolic acid, and its prodrug was introduced by Anthony Allison a geneticist from South African and his wife Elsie M Eugui during the early 1970s, and has been used as an antimetabolite immunosuppressive agent that work by inhibiting purine synthesis. 

Mycophenolic mofetil has been considered safe and useful in preventing the immune rejection of allografts since the early 1990s. Therefore, it has been increasingly used as an anti-rejection agent in organ transplants [48-50]. 

 

Figure-3: Bartolomeo Gosio (17 March17, 1863-April 13, 1944), an Italian medical scientist

In 1996, Confavreux and Moreau from France emphasized the available evidence suggesting that mycophenolate mofetil has a good safety profile and lacks mutagenic effect and chromosome breakage [51].

During the previous decades, mycophenolate mofetil has been used extensively with a beneficial effect in childhood nephrotic syndrome [52-68]. 

In our case, the combination of intramuscular synacthen and oral mycophenolate resulted in successful treatment without significant side effects, effectively minimizing steroid toxicity, particularly concerning psychiatric manifestations.

Conclusion

Childhood nephrotic syndrome remains a complex condition requiring a multifaceted approach to management, particularly in cases that are frequently relapsing or steroid-dependent. The historical evolution of understanding this disorder underscores the significance of ongoing research and innovation in treatment strategies.

The successful use of a combination therapy involving intramuscular synacthen and mycophenolate mofetil in the presented case demonstrates the potential for alternatives to traditional corticosteroid treatments. This approach not only alleviated the nephrotic syndrome symptoms but also mitigated the psychiatric side effects commonly associated with high-dose steroid therapy.

Future research should continue to explore and validate such therapeutic combinations to optimize outcomes for children with challenging nephrotic syndrome, aiming for effective management with minimal adverse effects.

Acknowledgement 

The author has the copyrights of all the sketches (Figures) included in this paper.

Conflict of interest: None.

 

References

  1. Johnson G (1846). On the minute anatomy and pathology of Bright's disease of the kidney, and on the relation of the renal disease to those diseases of the liver, heart, and arteries, with which it is commonly associated. Med Chir Trans 1846; 29:1-24.
    View at Publisher | View at Google Scholar
  2. Roelans C. Liber de Aegritudinibus Infantium. München: Verl. der Mu¨nchner Dr. (1484).
    View at Publisher | View at Google Scholar
  3. Zwinger T (1974). Anasarca puerorum. In: Basel E, Thurnis JR. editors. Paedioatreia Pract Curationem Puerorumque Morborum Puerilium etc 1974; 5: 659-666.
    View at Publisher | View at Google Scholar
  4. Bright R. Reports of Medical Cases. London: Orme; (1827).
    View at Publisher | View at Google Scholar
  5. Cameron JS (1994). John Bostock MD FRS (1773-1846): physician and chemist in the shadow of a genius. Am J Nephrol 1994; 14(4-6):365-70.
    View at Publisher | View at Google Scholar
  6. Müller F (1905). Morbus Brightii. Verh Dtsch Ges Path 1905; 9:64-99.
    View at Publisher | View at Google Scholar
  7. Volhard , Fahr T (1914). Die Brightsche Nieren krankheit Berlin. Springer Velag 1914.
    View at Publisher | View at Google Scholar
  8. Barnett HL, McNamara H, McCrory W, Forman C, Rapoport M, Michie A, Barbero G (1950). The effects of ACTH and cortisone on the nephrotic syndrome. AMA Am J Dis Child Sep; 80(3):519-20.
    View at Publisher | View at Google Scholar
  9. Rapoport M, McCrory WW, Michie AJ, Barbero G, Barnett HL,et.al (1951). Effects of corticotrophin on children with nephrotic syndrome: clinical observations on 34 children; the effect of cortisone in 4. AMA Am J Dis Child 1951 Aug; 82(2):248-53.
    View at Publisher | View at Google Scholar
  10. Arneil GC, Wilson HE (1952). Cortisone treatment of nephrosis. Arch Dis Child 1952 Aug; 27(134):322-8.
    View at Publisher | View at Google Scholar
  11. Arneil GC, Wilson HE (1953). A.C.T.H. in nephrosis. Arch Dis Child 1953 Oct; 28(141):372-80. 0
    View at Publisher | View at Google Scholar
  12. Lauson HD, Forman CW, McNamara H, Mattar G, Barnett HL (1954). The effect of corticotropin (ACTH) on glomerular permeability to albu¬min in children with the nephrotic syndrome. J Clin Invest 1954; 33: 657-664.
    View at Publisher | View at Google Scholar
  13. Arneil GC (1956). Treatment of nephrosis with prednisolone. Lancet 1956 Apr 14; 270 (6920): 409-11.
    View at Publisher | View at Google Scholar
  14. Prieto MM, Senet RE (1957). Seis casos de nefrosis lipoídica tratados con prednisolona [6 Cases of lipoid nephrosis treated with prednisolone]. Dia Med 1957 Dec 2; 29(87):3230-2.
    View at Publisher | View at Google Scholar
  15. Holland WW, Colley JR, Moore KA (1958). The nephrotic syndrome in children treated with a course of prednisolone. Br Med J 1958 Aug 23; 2(5094):479-81.
    View at Publisher | View at Google Scholar
  16. Fontan (1959). [Evaluation of corticotherapy in pediatric medicine]. J Med Bord 1959 Dec; 136: 1400-2 [Article in French].
    View at Publisher | View at Google Scholar
  17. Cameron JS (1968). Histology, protein clearances, and response to treatment in the nephrotic syndrome. Br Med J 1968 Nov 9; 4(5627):352-6.
    View at Publisher | View at Google Scholar
  18. Habib R, Kleinknecht C (1971). The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. Pathol Annu 1971; 6:417-74.
    View at Publisher | View at Google Scholar
  19. Grupe WE, Makker SP, Ingelfinger JR (1976). Chlorambucil treatment of frequently relapsing nephrotic syndrome. N Engl J Med 1976 Sep 30; 295(14):746-9.
    View at Publisher | View at Google Scholar
  20. Martini RJ, Gomila A, Solanas G (1977). Estudio longitudinal en niños con síndrome nefrótico y lesión glomerular mínima [Longitudinal study in children with the nephrotic syndrome and minimal glomerular lesion]. Bol Med Hosp Infant Mex 1977 Sep-Oct; 34(5):1105-16 [Article in Spanish].
    View at Publisher | View at Google Scholar
  21. Baluarte HJ, Hiner L, Gruskin AB (1978). Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. J Pediatr 1978 Feb; 92(2):295-8.
    View at Publisher | View at Google Scholar
  22. Guesry P, Lenoir G, Broyer M (1978). Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978 Feb; 92(2):299-303.
    View at Publisher | View at Google Scholar
  23. Wiggelinkhuizen J, McDonald R, van Dugteren GR (1979). Chlorambucil therapy in childhood nephrotic syndrome. S Afr Med J 1979 Jun 9; 55(24):971-5.
    View at Publisher | View at Google Scholar
  24. Williams SA, Makker SP, Ingelfinger JR, Grupe WE (1980). Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. N Engl J Med 1980 Apr 24; 302(17):929-33.
    View at Publisher | View at Google Scholar
  25. The international study of kidney disease. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr. 1979 Aug; 95(2):239-43.
    View at Publisher | View at Google Scholar
  26. Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S (1980). Treatment of nephrotic syndrome with levamisole. J Pediatr 1980 Mar; 96(3 Pt 1):490-3.
    View at Publisher | View at Google Scholar
  27. Niaudet P, Drachman R, Gagnadoux MF, Broyer M (1984). Treatment of idiopathic nephrotic syndrome with levamisole. Acta Paediatr Scand 1984 Sep; 73(5):637-41.
    View at Publisher | View at Google Scholar
  28. British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet. 1991 Jun 29; 337(8757):1555-7.
    View at Publisher | View at Google Scholar
  29. Capodicasa G, De Santo NG, Nuzzi F, Giordano C (1986). Cyclosporin A in nephrotic syndrome of childhood: A 14 month experience. Int J Pediatr Nephrol 1986 Apr-Jun; 7(2):69-72.
    View at Publisher | View at Google Scholar
  30. Brodehl J (1991). The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies. Eur J Pediatr 1991 Apr; 150(6):380-7.
    View at Publisher | View at Google Scholar
  31. Dayal U, Dayal AK, Shastry JC, Raghupathy P (1994). Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron 1994; 66(4):408-12.
    View at Publisher | View at Google Scholar
  32. Tenbrock K, Müller-Berghaus J, Fuchshuber A, Michalk D, Querfeld U (1998). Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. Pediatr Nephrol 1998 Aug; 12(6):459-62.
    View at Publisher | View at Google Scholar
  33. Fu LS, Shien CY, Chi CS (2004). Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Nephron Clin Pract. 2004; 97(4):c137-41.
    View at Publisher | View at Google Scholar
  34. Donia AF, Ammar HM, El-Agroudy Ael-B, Moustafa Fel-H, Sobh MA (2005). Long-term results of two unconventional agents in steroid-dependent nephrotic children. Pediatr Nephrol 2005 Oct; 20(10):1420-5.
    View at Publisher | View at Google Scholar
  35. Hafeez F, Ahmed TM, Samina U (2006). Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. J Coll Physicians Surg Pak 2006 Jan; 16(1):35-7.
    View at Publisher | View at Google Scholar
  36. Abeyagunawardena AS, Karunadasa U, Jayaweera H, Thalgahagoda S, Tennakoon S, Abeyagunawardena S (2017). Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome. Pediatr Nephrol 2017 Aug; 32(8):1363-1367.
    View at Publisher | View at Google Scholar
  37. Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A,et.al (2018); all members of the Levamisole Study Group. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int. 2018 Feb; 93(2):510-518.
    View at Publisher | View at Google Scholar
  38. Bhatt GC, Patel B, Das RR, Malik S, Bitzan M, et.al (2023). Efficacy and safety of levamisole in childhood nephrotic syndrome: A meta-analysis. Indian J Pharmacol 2023 Jan-Feb; 55(1):43-52.
    View at Publisher | View at Google Scholar
  39. Sinha A, Devi KG, Kalra S, Mani K, Hari P, Bagga A (2024). An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. Kidney Int 2024 May; 105(5):1113-1123.
    View at Publisher | View at Google Scholar
  40. Briggs WA, Choi MJ, Scheel PJ Jr (1998). Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998 Feb; 31(2):213-7.
    View at Publisher | View at Google Scholar
  41. Youssef DM, Abdelsalam MM, Abozeid AM, Youssef UM (2013). Assessment of behavior abnormalities of corticosteroids in children with nephrotic syndrome. ISRN Psychiatry. 2013 Apr 16; 2013:921253.
    View at Publisher | View at Google Scholar
  42. Berg AL, Arnadottir M (2004). ACTH-induced improvement in nephritic syn¬drome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004; 19:1305-1307.
    View at Publisher | View at Google Scholar
  43. Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007). Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007 Dec; 22(12):2059-65.
    View at Publisher | View at Google Scholar
  44. Gong R, Dworkin LD (2010). ACTH (Acthar gel) prevents proteinuria and renal injury in the remnant kidney: evidence for direct podocyte protection. J Am Soc Nephrol 2010; 21: 54 8A.
    View at Publisher | View at Google Scholar
  45. Gong R (2011). The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2011; 8:122-128.
    View at Publisher | View at Google Scholar
  46. Lorusso P, Bottai A, Mangione E, Innocenti M, Cupisti A, et.al (2015). Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. Int J Nephrol Renovasc Dis 2015 Feb 5; 8:7-12.
    View at Publisher | View at Google Scholar
  47. Chakraborty R, Mehta A, Nair N, Nemer L, Jain R, Joshi H, Raina R (2020). ACTH treatment for management of nephrotic syndrome: A systematic review and reappraisal. Int J Nephrol 2020 Jun 4; 2020:2597079.
    View at Publisher | View at Google Scholar
  48. Florey HW, Gilliver K, Jennings MA, Sanders AG (1946). Mycophenolic Acid. An Antibiotic from Penicillium brevicompactum Dierckx. The Lancet 1946: 46-49.
    View at Publisher | View at Google Scholar
  49. Haydon GH, Hayes PC (1994). New immunosuppressive treatment in transplantation medicine. Baillieres Clin Gastroenterol 1994 Sep; 8(3):455-64.
    View at Publisher | View at Google Scholar
  50. Al-Mosawi AJ (2023). The Use of Mycophenolate Mofetil in Psoriasis: An Educational Article and Expert Opinion. International Journal of Clinical Epidemiology (ISSN: 2835-9232) May 2023; 2(3):1-4.
    View at Publisher | View at Google Scholar
  51. Confavreux C, Moreau T (1996). Emerging treatments in multiple sclerosis: azathioprine and mofetil. Mult Scler 1996 Jul; 1(6):379-84.
    View at Publisher | View at Google Scholar
  52. Chandra M, Susin M, Abitbol C (2000). Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 2000 Mar; 14(3):224-6.
    View at Publisher | View at Google Scholar
  53. Zhao M, Chen X, Chen Y, Liu Z, Liu Y,et.al (2001). [Mycophenolate mofetil in the treatment of primary nephrotic syndrome]. Zhonghua Yi Xue Za Zhi 2001 May 10; 81(9):528-31 [Article in Chinese].
    View at Publisher | View at Google Scholar
  54. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ (2002). Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002 Mar; 61(3):1098-114.
    View at Publisher | View at Google Scholar
  55. Mogyorósi A, Lippman HR, Feldman GM (2002). Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil. Am J Nephrol 2002 Sep-Dec; 22(5-6):569-72.
    View at Publisher | View at Google Scholar
  56. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D (2002). Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002 Nov; 17(11):2011-3.
    View at Publisher | View at Google Scholar
  57. Zhao M, Chen X, Chen Y, Liu Z, Liu Y,et.al (2003). Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (Carlton). 2003 Jun; 8(3):105-9.
    View at Publisher | View at Google Scholar
  58. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003). Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 2003 Aug; 18(8):833-7.
    View at Publisher | View at Google Scholar
  59. Bagga A, Hari P, Moudgil A, Jordan SC (2003). Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003 Dec; 42(6):1114-20.
    View at Publisher | View at Google Scholar
  60. Gellermann J, Querfeld U (2004). Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004 Jan; 19(1):101-4.
    View at Publisher | View at Google Scholar
  61. Noroña B, Valentín M, Gutiérrez E, Praga M (2004). Tratamiento del síndrome nefrótico córtico-dependiente por lesiones mínimas con micofenolato mofetil [Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil]. Nefrologia 2004; 24(1):79-82 [Article in Spanish].
    View at Publisher | View at Google Scholar
  62. Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A,et.al (2006). Mykofenolan mofetilu w leczeniu dzieci z zespołem nerczycowym: doniesienie wstepne [Mycophenolate mofetil in treatment of childhood nephrotic syndrome: Preliminary report]. Przegl Lek 2006; 63 Suppl 3:44-8[Article in Polish].
    View at Publisher | View at Google Scholar
  63. Tasanarong A, Thitiarchakul S (2006). Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome. J Med Assoc Thai 2006 Aug; 89 Suppl 2:S218-27.
    View at Publisher | View at Google Scholar
  64. Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N (2006). Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006 Nov; 1(6):1173-8.
    View at Publisher | View at Google Scholar
  65. Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007). Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007 Dec; 22(12):2059-65.
    View at Publisher | View at Google Scholar
  66. Yi ZW, Dang XQ, He QN, Wu XC, Cao Y, et.al (2007). Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children. 2007 Dec; 32(6):938-40.
    View at Publisher | View at Google Scholar
  67. Yi ZW, Wu XC, Xu H, Zhou LJ, Wu YB,et.al (2008). [A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children]. Zhongguo Dang Dai Er Ke Za Zhi 2008 Oct; 10(5):575-8 [Article in Chinese].
    View at Publisher | View at Google Scholar
  68. Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL,et.al (2012). Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 2012 Mar; 27(3):389-96.
    View at Publisher | View at Google Scholar

Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.

img

Virginia E. Koenig

Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.

img

Delcio G Silva Junior

Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.

img

Ziemlé Clément Méda

Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.

img

Mina Sherif Soliman Georgy

We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.

img

Layla Shojaie

The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.

img

Sing-yung Wu

Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.

img

Orlando Villarreal

Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.

img

Katarzyna Byczkowska

Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.

img

Anthony Kodzo-Grey Venyo

Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.

img

Pedro Marques Gomes

Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.

img

Bernard Terkimbi Utoo

This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.

img

Prof Sherif W Mansour

Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.

img

Hao Jiang

As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.

img

Dr Shiming Tang

Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.

img

Raed Mualem

International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.

img

Andreas Filippaios

Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.

img

Dr Suramya Dhamija

Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.

img

Bruno Chauffert

I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!

img

Baheci Selen

"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".

img

Jesus Simal-Gandara

I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.

img

Douglas Miyazaki

We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.

img

Dr Griffith

I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.

img

Dr Tong Ming Liu

I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.

img

Husain Taha Radhi

I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.

img

S Munshi

Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.

img

Tania Munoz

“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.

img

George Varvatsoulias

Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.

img

Rui Tao

Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.

img

Khurram Arshad

Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.

img

Gomez Barriga Maria Dolores

The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.

img

Lin Shaw Chin

Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.

img

Maria Dolores Gomez Barriga

Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.

img

Dr Maria Dolores Gomez Barriga

Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.

img

Dr Maria Regina Penchyna Nieto

Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.

img

Dr Marcelo Flavio Gomes Jardim Filho

Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”

img

Zsuzsanna Bene

Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner

img

Dr Susan Weiner

My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.

img

Lin-Show Chin

My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.

img

Sonila Qirko

My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.

img

Luiz Sellmann